STAT

Grandstanding, not real change: Why drug prices in TV ads will be confusing and irrelevant

In TV drug ads, the numbers that will soon flash across screens are likely to be confusing and, in many cases, irrelevant.

In a fit of hubris, President Trump believes he is making drug makers “come clean” by forcing them to mention list prices in their TV ads.

If only it were that simple.

The reality is that last week’s mandate may, indeed, prod recalcitrant drug makers to pay more attention to pricing and, in some cases, cast this or that company in a greedy light. But for the most part, the numbers that will soon flash across screens are likely to be confusing and, in many cases, irrelevant.

Why do I say that?

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks